Navigation Links
BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
Date:12/7/2009

ut PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include (1) SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine, (2) Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection, (3) Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents, (4) RypVax(TM) - a recombinant dual antigen vaccine for plague, and (5) a third generation rPA anthrax vaccine.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) unde
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
2. ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement
5. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Gamida Cell Announces Feasibility Study With Weill Cornell Medical College
8. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
9. Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia
10. PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT
11. Ohio Capital Fund Announces Sponsorship of Minority Business Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 The National ... in Muncie IN, is pleased to announce that it ... National Museum of the United States Air Force. , ... year-long process that concluded this spring with an on-site ... Dayton, OH museum. , The National Museum of ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... live in each person,s digestive tract. Scientists believe that ... off harmful infections, but their role in human health ... on the role of these bacteria, a team of ... tracked fluctuations in the bacterial populations of two research ... the July 25 issue of the journal Genome ...
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
Breaking Biology Technology:AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... Supports Program to Recognize Exemplary Work, BRIDGEWATER, ... of oncology nurses, Ortho Biotech Products, L. P.,today ... Healer,Award for Oncology Nursing, which honors one of ... their unwavering,dedication, compassion and helpfulness. Last year, more ...
... Exclusive Rights to Oncology Biomarkers, FREMONT, ... VRML ), a high-value molecular diagnostics company, ... with Johns Hopkins University,on the development of ... disease,detection, classification and monitoring of prevalent cancers, ...
... Pharmaceuticals,Inc. (NYSE: BRL ) today announced that its ... Merck & Co., Inc.,s Fosamax(R),(Alendronate Sodium) Tablets, 70 mg ... Administration (FDA)., The FDA approved the Company,s application ... associated with the,earliest to expire of the patents listed ...
Cached Biology Technology:Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing 2Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 3Barr Launches Generic Fosamax(R) Tablets, 70 mg 4
(Date:7/27/2014)... data from over 18,000 patients, scientists have identified ... in Parkinson,s disease, including six that had not ... Nature Genetics , was partially funded by the ... scientists working in NIH laboratories. , "Unraveling the ... the multiple mechanisms involved in this complex disease, ...
(Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
(Date:7/25/2014)... raging this summer and some of the smoke from those ... image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... smoke has descended over the Great Lakes region of the ... image from July 23, 2014 (first image feature highlighted below) ... off southeastward. In the image, it is over Manitoba ...
Breaking Biology News(10 mins):NIH scientists find 6 new genetic risk factors for Parkinson's 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... never reach the tumors they,re intended to treat, ... the blood vessels feeding the tumors are abnormal"leaky ... Judah Folkman, MD, founder of the Vascular Biology ... researchers have discovered an explanation for these abnormalities ...
... 75% of fertilizers and fertilizer technology used around the ... to 1970s by scientists and engineers at the Tennessee ... Shields, a former TVA official. Shields is now Interim ... and Agricultural Development, based in Muscle Shoals, Alabama. ...
... A group of Yale undergraduates have discovered dozens of ... the Amazon rain forest, including several so genetically distinct ... taxonomical genera. The analysis of 135 endophytes - ... of plants - by members of the Rain Forest ...
Cached Biology News:Normalizing tumor vessels to improve cancer therapy 2Normalizing tumor vessels to improve cancer therapy 3TVA fertilizer technology used worldwide -- but few new products since 1970s 2TVA fertilizer technology used worldwide -- but few new products since 1970s 3TVA fertilizer technology used worldwide -- but few new products since 1970s 4Yale undergrads' Amazon trip yields a treasure trove of diversity 2
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
fli-1...
Vesicle Associated Membrane Protein (VAMP 1/2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Biology Products: